Market Size of Middle East And Africa Meglitinide Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | 4.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Middle East And Africa Meglitinide Market Analysis
The Middle-East and Africa Meglitinide Market size is estimated at USD 0.2 billion in current year, and is expected to reach USD 0.3 billion by forecast year, growing at a CAGR of 4% during the forecast period.
COVID-19 and diabetes have a significant impact on public health in the Middle East and Africa, as well as elsewhere. Diabetes has been linked to an increased risk of fatal infections and severe infections in COVID-19 patients. Because diabetes is one of the most common health problems in the Middle East and Africa, the current study focused on understanding the epidemiology of COVID-19 in diabetics and the strategies put in place by governments to mitigate its impact. In light of the importance and necessity of the epidemic, countries in the Middle East and Africa have implemented a number of preventative and control measures.
Meglitinides are a type of non-sulfonylurea insulin secretagogues with a fast onset and short duration of action. They stimulate glucose-sensitive first-phase insulin release, lowering the risk of hypoglycemia. Meglitinides cause the body to release more insulin in people with type 2 diabetes, who have chronically high blood sugar levels. The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products. This is driving the demand for Meglitinides in Middle-East and Africa, thereby driving the market in focus during the forecast period.
Middle East And Africa Meglitinide Industry Segmentation
Meglitinides, or glinides, are a class of drugs used to treat type-2 diabetes. The Middle East and Africa meglitinide market is segmented by drug (meglitinides), and geography (Iran, Saudi Arabia, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD) and volume (in units) for the above segments. This report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Drug | |
| Meglitinides |
| Geography | |
| South Africa | |
| Saudi Arabia | |
| Oman | |
| Egypt | |
| Iran | |
| Rest of Middle East and Africa |
Middle East And Africa Meglitinide Market Size Summary
The Middle East and Africa meglitinide market is poised for growth, driven by the increasing prevalence of diabetes in the region. Meglitinides, a class of non-sulfonylurea insulin secretagogues, play a crucial role in managing type 2 diabetes by stimulating insulin release and reducing the risk of hypoglycemia. The market is influenced by the rising diabetes population, with significant efforts from governments to enhance diabetes prevention and control measures. The World Health Assembly's resolution to strengthen diabetes management and the focus on increasing access to diabetes medications are key factors propelling the demand for meglitinides. Despite the challenges posed by COVID-19, which has exacerbated health issues for diabetics, the market is expected to expand as countries implement strategies to mitigate these impacts.
In Saudi Arabia, a significant contributor to the regional market, the government is actively working to reduce diabetes prevalence through various initiatives, such as taxing sugary drinks and promoting physical fitness. The availability of meglitinides like repaglinide and nateglinide, approved for use in type 2 diabetes patients, further supports market growth. The competitive landscape is characterized by the presence of global manufacturers like Novo Nordisk, Glenmark, and Novartis, alongside generic drug producers. Ongoing clinical trials and research continue to evaluate the efficacy of meglitinides, reinforcing their importance in diabetes management. As the market evolves, these factors collectively contribute to the anticipated growth of the meglitinide market in the Middle East and Africa over the forecast period.
Middle East And Africa Meglitinide Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Drivers
-
1.3 Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. Market Segmentation
-
2.1 Drug
-
2.1.1 Meglitinides
-
-
2.2 Geography
-
2.2.1 South Africa
-
2.2.2 Saudi Arabia
-
2.2.3 Oman
-
2.2.4 Egypt
-
2.2.5 Iran
-
2.2.6 Rest of Middle East and Africa
-
-
Middle East And Africa Meglitinide Market Size FAQs
What is the current Middle East And Africa Meglitinide Market size?
The Middle East And Africa Meglitinide Market is projected to register a CAGR of 4% during the forecast period (2024-2029)
Who are the key players in Middle East And Africa Meglitinide Market?
Novo Nordisk, Glenmark, Kissei, Novartis and Biocon are the major companies operating in the Middle East And Africa Meglitinide Market.
